| P2093 | author name string | Janknegt R | |
| P2860 | cites work | In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice | Q28359886 |
| | Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions | Q28361539 |
| | Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals | Q28361543 |
| | Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides | Q28361967 |
| | Aminoglycoside binding sites in the inner ears of guinea pigs | Q35298440 |
| | Influence of hydrocortisone on gentamicin-induced nephrotoxicity in rats | Q35312576 |
| | Antimicrobial susceptibility patterns of Nocardia asteroides | Q35565721 |
| | Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations | Q35674282 |
| | Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy | Q38596243 |
| | Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions | Q39589814 |
| | Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985. | Q39589831 |
| | Aminoglycosides: current role in antimicrobial therapy | Q39608639 |
| | Aminoglycoside antibiotics in clinical use. | Q39634450 |
| | Aminoglycosides: a reassessment of their therapeutic role | Q39647873 |
| | Aminoglycoside nephrotoxicity | Q39648907 |
| | Aminoglycoside nephrotoxicity in obstructive jaundice | Q39712875 |
| | Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides | Q39738110 |
| | Aminoglycoside antibiotics in infectious diseases. An overview | Q39738119 |
| | Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside | Q39738131 |
| | An overview of amikacin | Q39819199 |
| | Netilmicin (Netromycin, Schering-Plough). | Q40144922 |
| | A study of amikacin given once versus twice daily in serious infections | Q41274203 |
| | The lethal action of aminoglycosides | Q41946737 |
| | Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis | Q42660646 |
| | Combination therapy: a way to limit emergence of resistance? | Q43504823 |
| | Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients | Q44126937 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Gentamicin bioavailability and single-dose pharmacokinetics in spinal cord injury | Q46665163 |
| | Alterations in aminoglycoside volume of distribution in patients below ideal body weight | Q47198985 |
| | Multivariate analysis of aminoglycoside levels in hemodialysis patients. | Q52544033 |
| | An international study on the occurrence of multiresistant bacteria and aminoglycoside consumption patterns. | Q53413745 |
| | The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin. | Q54399156 |
| | Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin. | Q54426427 |
| | Aminoglycoside Ototoxicity: Influence of Dosage Regimen on Drug Uptake and Correlation between Membrane Binding and some Clinical Features | Q58290011 |
| | Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis | Q67931093 |
| | The choice of antimicrobial drugs | Q68091489 |
| | Early synergistic killing activity at concentrations attainable in CSF of amoxicillin or cefotaxime and aminoglycosides against Haemophilus influenzae | Q68093859 |
| | In vitro susceptibility to aminoglycoside antibiotics in blood and urine isolates consecutively collected in twenty-nine European laboratories. European Study Group on Antibiotic Resistance | Q68194936 |
| | Impact of dosage regimens on the efficacy of antibiotics in the immunocompromised host | Q68327882 |
| | Individualized aminoglycoside dosage regimens in patients with cystic fibrosis | Q68434045 |
| | Excessive aminoglycoside nephrotoxicity in obese patients | Q68461443 |
| | A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections | Q69522572 |
| | Experimental studies on nephrotoxicity of aminoglycosides at low doses. Mechanisms and perspectives | Q69561816 |
| | Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity | Q69561833 |
| | Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis | Q69921829 |
| | Once-daily dosing decreases renal accumulation of gentamicin and netilmicin | Q69936275 |
| | Cost-effective aminoglycoside therapy in surgical patients | Q70297319 |
| | Susceptibility of streptomycin-resistant Mycobacterium tuberculosis strains to amikacin | Q70395093 |
| | Comparative study on antagonistic effects of low pH and cation supplementation on in-vitro activity of quinolones and aminoglycosides against Pseudomonas aeruginosa | Q70405369 |
| | Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method | Q70405372 |
| P433 | issue | 3 | |
| P304 | page(s) | 81-90 | |
| P577 | publication date | 1990-06-01 | |
| P1433 | published in | Pharmaceutisch weekblad. Scientific edition | Q27712605 |
| P1476 | title | Aminoglycoside therapy. Current use and future prospects | |
| P478 | volume | 12 | |